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Abstract
Objective To identify patients at very high risk for
adverse pregnancy outcome (APO) at the 20- to 23-week
scan and to assess the effectiveness of Aspirin (ASS) and
low molecular weight heparin (LMWH) starting after this
examination.
Patients and methods By applying an algorithm based on
multivariate logistic regression analysis using the parame-
ters maternal age, parity, body mass index (BMI), mean
pulsatility index of both uterine arteries (meanPI), presence
of uni- or bilateral notch, and depth of notch (mean notch
index (meanNI), we retrospectively calculated the indi-
vidual risk for APO of 21,302 singleton pregnancies. We
isolated a subgroup of 426 patients with the highest cal-
culated probability for APO (cpAPO [ 27.8 %). 147 had
been treated with ASS; 73 with LMWH, 15 patients with a
combination of ASS and LMWH, and 191 patients had not
received anticoagulants.
Results Administration of ASS starting after 20 gesta-
tional weeks in comparison to non-treated patients signif-
icantly reduced the frequency of intrauterine/neonatal
death (IUD/NND), preeclampsia \33 weeks (PE \ 33),
and preterm delivery \33 weeks (PD \ 33), while the
frequency of IUGR showed a tendency to be elevated
(P = 0.061). The subgroup of high-risk patients treated
with LMWH was characterised by a higher a priori risk for
APO and showed no significant reduction of any form of
APO but an increased frequency of PE.
Conclusion Individual assessment of risk for APO by
applying a simple algorithm based on biometrical/bio-
graphical as well as sonographic parameters may serve as
basis for drug intervention studies. The administration of
ASS in high-risk patients starting after 20 gestational
weeks reduced the frequency of most of the severe forms of
adverse pregnancy outcome in high-risk patients. A com-
plication-reducing effect of LMWH starting after 20 weeks
of gestation in patients could not be proven. From an
ethical point of view, it may not be justified any more to
preclude high-risk patients from administration of ASS or
to perform studies of ASS against placebo.
Keywords Low molecular weight heparin  ASS 
Adverse pregnancy outcome  Preeclampsia
Introduction
Preeclampsia (PE), intrauterine growth restriction (IUGR),
placental abruption, intrauterine or neonatal death (IUD/
NND), and preterm delivery (PD) are important contribu-
tors to both perinatal and maternal morbidity and mortality
[1–3]. Meanwhile, it is well known that at least part of
these forms of adverse pregnancy outcome (APO), which
mostly find their manifestation in the third trimester of
pregnancy, have their origin in pathological trophoblast
invasion which occurs in the first trimester of pregnancy
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[2, 4, 5]. More than 25 years ago, it could be shown that
assessment of uterine artery Doppler waveforms (assess-
ment of impedance as well as presence of notch) in the
second trimester [6, 7] could predict some of the cases of
APO. Quantification of the depth of notch was not per-
formed. Meanwhile, the identification of high-risk patients
has been improved by the introduction of other parameters
like patient history (e.g., APO in prior pregnancy), bio-
physical parameters like elevated maternal age, elevated
maternal body mass index (BMI) [8] or pre-existing
maternal hypertension. Combination with certain serum
markers gave additional information on the probability of
APO [9–17]. Also the presence of thrombophilia is in
discussion to be a contributing factor [2, 18–24].
Important consequence of the identification of a high-
risk situation for APO in the first trimester is the admin-
istration of anticoagulants. The use of ASS to prevent APO
had been introduced by Wallenburg [25] and later was
shown to be effective in many studies [26–29] and several
meta-analyses [30–37]. It is well known that up to now the
effect of pharmaceutical interventions cannot yet be a
complete prevention but a reduction of frequency and
intensity of complications [12, 16, 38–40]. Recent research
shows that this effect for ASS is higher if administered in
high-risk patients before 16 weeks in comparison to later
administration [35–37]. Also other drugs like low molec-
ular weight heparin (LMWH) were shown to be possibly
effective in the prevention of APO [41–44].
At the moment, we are far away from a situation where
every woman has access to a first trimester risk assessment
of APO including additional cost producing assessment of
serum parameters [45]. Therefore, we still have to be
prepared to a situation when we have to assess the proba-
bility of APO and identify patients at high risk for APO for
the first time in the second trimester. It is unclear how
effective ASS and LMWH are in high-risk patients if their
administration starts after 20 weeks.
In prior studies, we had shown that depth of notch is an
easily determinable parameter that gives important addi-
tional information for risk assessment of APO [46, 47]. We
had developed an algorithm to quantify the probability for
APO based on a combination of biographical (parity),
biometrical (BMI) and the sonographic parameters
impedance of uterine arteries as well as presence and depth
of notch—a risk assessment for APO which can be per-
formed easily and fast without additional laboratory cost as
part of the second trimester anomaly scan [3].
The aim of this retrospective evaluation was to find out
whether patients being identified by our algorithm at the
20 ? 0- to 23 ? 6-week scan to be at very high risk for
APO did have benefit of administration of ASS and
LMWH starting at this time in comparison to non-treated
patients.
Patients and methods
Covering a time span of 17 years (January 1994–December
2010), a total of 22,349 patients had been examined ful-
filling the following criteria:
– singleton pregnancy from 20 ? 0 to 23 ? 6 gestational
weeks
– viable foetus without major malformation detected
during pregnancy of within the first 10 neonatal days
– duration of pregnancy more than 24 weeks
– well-known parameters maternal age, BMI and parity
(questioned at the time of ultrasound)
– well-known results of Doppler sonography of both
uterine arteries pulsatility index (PI) and notch index
(NI)
The vast majority of the patients was referred to our
center for a routine second trimester anomaly scan. The
outcome of 21,302 of these pregnancies (95.3 %) was well
known including information on duration of pregnancy and
occurrence of any form of adverse pregnancy outcome
(APO) mentioned below. In 10,365 cases, a feedback form
which the patients had received at the end of the exami-
nation was returned to us. For further 10,937 cases, women
were contacted by telephone by the staff of our office
starting 4 weeks after the estimated date of delivery. The
staffs were not informed on the result of the ultrasound
examination at the time of contact.
The major part of this study group had been evaluated
before [3] with the difference of having excluded all
patients having been treated with anticoagulants. With this
prior evaluation, we had created and validated a multi-
variate approach for the prediction of adverse pregnancy
outcome (APO) defined as
– PD \ 33 gestational weeks (PD \ 33),
– IUGR (defined as a birth weight equal to or smaller
than the 5th centile of sex-adjusted birth weight
according to a German control group [48],
– PE defined as proteinuric pregnancy induced hyperten-
sion with two recordings of diastolic blood pressure of
[90 mm Hg and proteinuria of [300 mg/24 h or ??
or more on dipstick testing,
– PA (based on the clinical symptom of severe bleeding
leading to the clinical consequence of emergency
delivery and assessment by the physician in charge as
placental abruption),
– IUD/NND,
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– presence of notch (no, unilateral, bilateral),
– mean of Pulsatility Index (PI) of right and left uterine
artery (meanPI), and
– mean of Notch-Index (NI) of right and left uterine
artery (meanNI) [3, 44].
In the present retrospective evaluation, we additionally
included a total number of 630 patients who had been
treated with anticoagulants: 389 with ASS (100 mg), 197
with LMWH (5.000 IU/d) and 44 with a combination of
ASS and LMWH. 235 of these 630 patients received
anticoagulants following the 20 ? 0- to 23 ? 6-week scan
because they were believed to be at high risk for APO
based on the parameters available at this time (high
impedance of uterine arteries, presence of notch). The other
395 patients undergoing anticoagulant therapy were not at
high risk for APO and had received medication beginning
at earlier stages of pregnancy for reasons deriving of
problems of internal medicine (for example history of
thrombosis) or because of a history of multiple abortions.
Out of these 21,302 patients, those with a risk exceeding
the 98th centile (27.8 %) for calculated probability of APO
(cpAPO) (n = 426) were selected for further evaluation
and formed a subgroup of 426 high-risk patients. Evalua-
tion was performed with SAS 9.2 (SAS Institute Inc., Cary,
NC, USA).
Statistical tests were applied for an exploratory analysis
without correction for multiple testing. Contingency tables
were analyzed with v2 test (in case of at one or more
expected frequencies \5 with Fisher’s exact test). LOESS
regression was used in terms of a smoothing technique to
visualise dependency of fraction of complications on
cpAPO.
Results
The observed frequencies of adverse pregnancy outcome in
21,302 patients are demonstrated in Table 1. Table 2
describes the percentiles of the calculated probabilities of
APO for the 21,302 patients. To get an impression of a
possible effect of ASS alone or LMWH alone on the fre-
quency of observed APO, we performed a LOESS—
regression for all 1.254 complications in 21,258 patients
(Fig. 1) after having excluded 44 patients with a combined
medication of LMWH plus ASS. In patients without anti-
coagulant therapy, the figure shows the steadily ascending
relation between calculated and observed frequencies of
complication which is due to the construction of the
cpAPO risk predictor. Both ASS and LMWH had a com-
plication-reducing effect in patients at very high risk for
APO. The effect was less pronounced and started in
patients with higher cpAPO values in the LMWH group.
Anticoagulant therapy was started with ASS in 147
patients, with LMWH alone in 73 patients and with a
combination of LMWH and ASS in 15 patients; 191
patients did not receive an anticoagulant therapy. None of
the 426 patients of the high-risk subgroup had received
anticoagulants during this pregnancy up to this time. BMI,
age and cpAPO of the different groups of intervention are
described in Table 3. The groups were comparable with the
exception of a higher value of cpAPO in ASS patients in
comparison to non-treated patients and in LMWH patients
in comparison to ASS and non-treated patients.
Table 4 gives an overview on the frequency of different
forms of APO in all patients as well as patients with and
without ASS and LMWH as well as the statistical analysis
of differences of the frequency of all forms of APO. In all
groups, the observed frequency of complications
(39.3–45.1 %) exceeded the predicted minimal frequency
of 27.8 % (P 98). The effect of ASS in comparison to
patients without anticoagulants was a significant reduction
of IUD/NND, PD \33 weeks and PE \ 33 weeks as well
as a non-significant tendency of lower frequencies of PA as
well as PE. The frequency of IUGR was slightly higher
with no statistical significance. The subgroup with LMWH
treatment starting with a higher calculated probability for
APO in comparison to the ASS and non-treated group did
not show a significant reduction of any form of APO; in
contrary, for PE and for the sum of all complications, there
was a significant increase.
Discussion
With a frequency of APO of 5.95 %, in sum, the whole
study group a priori fulfilled the criteria of a ‘‘low’’ or
‘‘normal’’ risk group. Application of the algorithm for
individual risk calculation showed the heterogeneity of this
group consisting of patients with a range from a very low to
a very high probability of APO (Table 2).
Table 1 Frequency of observed forms of APO in 21,302 patients
Complication n %
PD \ 33 207 0.97
PE 297 1.39
PE \ 33 39 0.18




PD \ 33 preterm delivery \33 gestational weeks, PE preeclampsia,
PE \ 33 preeclampsia delivered\33 weeks, IUGR B P5 intrauterine
growth restriction at or below 5th percentile, PA placental abruption,
IUD/NND intrauterine death/neonatal death
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Table 3 shows the biological data as well as the calcu-
lated frequencies of APO in relation to non-medication as
well as application of ASS and LMWH. While there was
no significant difference between the groups concerning
BMI and age, the cpAPO values of the three groups dif-
fered significantly. With a cpAPO value of 43.0, the ASS
group had a significantly higher a priori probability in
comparison to the non-treated group (cpAPO of 40.6 %).
With a cpAPO value of 48.3, the LMWH group had a
significantly higher a priori probability for APO in com-
parison to both the ASS group as well as the non-treated
group. These differences may—at least partly—contribute
to the results shown in Table 4. With an observed fre-
quency of 39.5 % in ASS patients, there was no significant
difference to the observed frequency of 39.3 % in patients
without treatment. Regarding the different forms of APO,
in spite of the higher a priori probability of APO in the ASS
group, there was a significant complication-reducing effect
Table 2 Percentiles of calculated frequencies of complications in 21,302 patients
cpAPO 1.3 % 2.2 % 2.5 % 4.3 % 8.8 % 13.2 % 27.8 % 42.9 % 93.6 %
Percentile min 5 10 50 90 95 98 99 Max
cpAPO Calculated probability of adverse pregnancy outcome
Fig. 1 Relation of observed and calculated complications depending
on mode of anticoagulation visualized by LOESS—regression
analysis of 1,254 complications in 21,258 patients (excluding 44
patients with LMWH plus ASS, 14 of them with complications)
Table 3 Descriptive statistics (median, range) for BMI, age, and cpAPO (calculated probability for adverse pregnancy outcome) for all 426
high-risk patients as well as the subgroups without and with anticoagulant therapy (ASS or LMWH or both, ASS only, LMWH only)
All No therapy ASS only LMWH only
426 100 % 191 44.8 % 147 34.5 % 73 17.1 %
BMI 24.2 (16.7–46.4) 23.5 (16.7–42.5) 23.9 (17.2–44.1) 24.8 (18.2–46.4)
Age 32 (14–45) 32 (15–44) 32 (17–45) 33 (19–43)
CpAPO 42.9 (27.9–93.6) 40.6 (27.9–82.8) 43.0 (27.9–88.1) p = 0.035* 48.3 (29.0–93.6) p = 0.002**
* Result of Mann–Whitney’s U test versus no therapy
** Result of Mann–Whitney’s U test versus ASS
Table 4 Absolute and relative frequencies of complications in high-risk patients in dependence on no treatment as well as ASS or LMWH
treatment
Complication All (n = 426) No therapy (n = 191) ASS only (n = 147) P LMWH only (n = 73) P
IUGR 82 (19.3 %) 30 (15.7 %) 35 (23.8 %) 0.061 (:) n.s. 13 (17.8 %) n.s.
IUD/NND 10 (2.3 %) 10 (5.2 %) 0 (0 %) 0.006 ; 0 (0 %) 0.066 (;) n.s.
PA 15 (3.5 %) 8 (4.2 %) 2 (1.4 %) n.s. 4 (5.5 %) n.s.
PD \ 33 56 (13.1 %) 32 (16.8 %) 11 (7.5 %) 0.011 ; 12 (16.4 %) n.s.
PE 84 (19.7 %) 38 (19.9 %) 19 (12.9 %) n.s. 24 (32.9 %) 0.026 :
PE \ 33 29 (6.8 %) 18 (9.4 %) 4 (2.7 %) 0.013 ; 6 (8.2 %) n.s.
All complications 181 (42.5 %) 75 (39.3 %) 5 8(39.5 %) n.s 40 (54.8 %) 0.023 :
Please note that several types of complications could occur in parallel. Result of statistical test (v2 test) for comparison of fractions of patients
with complications between ASS treatment and non-treatment as well as LMWH treatment and non-treatment (: elevated fraction, ; decreased
fraction)
PD \ 33 preterm delivery \ 33 gestational weeks, PE preeclampsia, PE \ 33 preeclampsia delivered \ 33 weeks, IUGR B P5 intrauterine
growth restriction at or below 5th percentile, PA placental abruption. IUD/NND intrauterine death/neonatal death
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of ASS for IUD/NND, PD \ 33 and PE \ 33. These data
confirm prior reports [26–37] showing a complication-
reducing effect of ASS in high-risk patients. In addition,
the data also show that the protecting effect of ASS even is
present if the administration starts in the second half of
pregnancy.
In contrast, there was a—non significant (P = 0.061)—
increasing effect of ASS on the frequency of IUGR. While
the majority of studies focus on the influence of ASS on
PE, the observation of the influence of ASS on IUGR is
limited [36, 49]. The tendency of higher frequencies of
IUGR in our retrospective evaluation may be partly
explained by a pregnancy-prolonging effect of ASS which
decreases the frequency of the severest complications
PD \ 33, PE \ 33 and IUD/NND perhaps inducing the
effect of a higher frequency of (surviving) IUGR babies. It
also has to be kept in mind that the a priori probability in
the ASS group was significantly higher than that in the
non-treated group. In addition, the late beginning of
administration of ASS may play a role in the elevated
frequency of IUGR in ASS patients. In a meta-analysis of
27 studies, it was shown that the reducing effect of ASS on
IUGR was only seen if administration started before
16 weeks [36].
There is evidence that the complication-reducing effect
is restricted to high-risk patients. In low-risk patients, ASS
was not effective in reducing the risk [30]. The method of
identifying high-risk patients may be a reason why some
studies did find only moderate effect of ASS or even no
effect at all [26, 28, 29]. Our method based on biophysical
and sonographic data only has proved to be effective in
identifying patients at high risk for APO [3]. In addition, it
has the advantage of being cost-effective. The more
affordable and practicable a method of prediction is, the
greater is the chance of increasing the number of patients
who might potentially take advantage from prediction and
following therapeutics. From an ethical perspective which
takes questions of justice and allocation into account, one
might argue that it would be desirable to give access to
prediction and treatment of APO to as many women as
possible which is facilitated if the method is cheap, simple,
safe, and fast. The additional measurement of serum
parameters only in patients identified by this algorithm to
be at high risk may increase cost-effectiveness in com-
parison to a concept of primary serum parameter mea-
surement in all patients.
There is little evidence that also Heparin and LMWH
alone or in combination with ASS [41, 50, 51] may have
beneficial effects in high-risk pregnancies to prevent PE
and IUGR [52]. Some observational as well as randomised
[51] studies have shown a protective, complication-reduc-
ing effect of LMWH in thrombophilic [41, 43] as well as in
non-thrombophilic patients [42, 44]. But not all studies
could show a protective effect of heparin [52, 53]. The
evidence showing the potential of LMWH to prevent
recurrence of PE is limited, so the use of Heparin and
LMWH is considered to be experimental [54]. Our retro-
spective evaluation could not show a complication-reduc-
ing effect of LMWH administration if started in the second
half of pregnancy. In contrast to ASS, our 73 patients
treated with LMWH did not show a significant reduction or
mitigation of any form of APO. This may partly be
explained by some of the shortcomings of the study: it was
not prospective double-blinded, but retrospective; there
was a significantly higher median of cpAPO especially in
patients treated with LMWH, so the LMWH group con-
tained patients with a significantly higher risk of APO.
Another factor may be the smaller number of patients of
the LMWH group. And it cannot be excluded that LMWH
has a protecting effect only if administration starts early in
pregnancy.
There are several more shortcomings of the study that
have to be mentioned. This retrospective evaluation covers
a long time period in which also other measures of treat-
ment like intensity of survey of high-risk pregnancies or
the quality of neonatal care may have changed. The algo-
rithm applied here is based on few parameters and does not
regard important factors like patient’s history, pre-existing
morbidity like hypertension, thrombophilia or other rele-
vant maternal diseases.
A crucial point is the indication of anticoagulants.
During the time of this retrospective analysis, we did not
have an algorithm to quantify the risk for APO, so there
was no clear basis for indication and mode of intervention
with the consequence of intervention on a subjective
arbitrary basis. Also the situation of published evidence
appeared to shift from a preferential administration of ASS
to a more positive view of the impact of LMWH. The mode
of interventions changed with time with a higher frequency
of patients treated with ASS at the beginning of the
observation and a change to a higher frequency of appli-
cation of LMWH in the later years. The patients were
primarily surveyed by their gynecologist and sent to our
center for the ultrasound examination. The decision whe-
ther and which anticoagulant was administered often based
on subjective parameters. So besides objective factors like
allergy against ASS, there were also reasons like antipathy
of the patient against injections or refusal of the referring
physician to administer expensive drugs. We cannot
exclude that other unknown confounders might have
influenced the results.
These findings suggest further research on the question
as to which patients had most benefit from which alterna-
tive prophylactic medication. However, prospective, ran-
domized trials in pregnant women face severe ethical
problems. Above all, researchers fear danger for the fetus.
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Experiences of teratogenic effects of administered drugs
and other dangers for mother and fetus through, for
example, placenta crossing drugs have resulted in ethics
guidelines restricting research with pregnant women [55,
56]. Pregnant women are often excluded from research,
and ethicists start to claim that research within this group
has become a ‘‘moral imperative’’, because ‘‘if a population
is going to use a medication, it must be studied in that
population’’ [57]. At the same time, these authors warn that
risk–benefit trade off between woman and fetus need to be
managed by several safeguards. One of these safeguards
includes the pursuit of innovative study designs. We argue
that retrospective research designs serve the purpose of
reducing risks by preselecting rational and reasonable
hypotheses for further prospective studies that have a low-
risk profile and are beneficial for the study participants.
Retrospective data offer indispensable information about
the safety, effectiveness, and efficiency of interventions.
Our data show that also the administration of anticoag-
ulants starting in the second half of pregnancy is of
advantage for high-risk patients. As a consequence, we raise
doubt that regarding the body of evidence concerning ASS
it may be justified not to administer anticoagulants in high-
risk patients or to perform studies of ASS against placebo.
With regard to the evaluation of our data, the effec-
tiveness of a medication of LMWH beginning in the sec-
ond half of pregnancy stays unclear. At least, we could not
show a beneficial effect of LMWH—which is much more
expensive than ASS—beginning at the second half of
pregnancy. To clear the situation, a prospective study—
perhaps ASS alone against LMWH as well as a combina-
tion of both—might be helpful.
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